Back to Journals » OncoTargets and Therapy » Volume 10

Novel insights into circular RNAs in clinical application of carcinomas

Authors Rong D, Tang W, Li Z, Zhou J, Shi J, Wang H, Cao H

Received 10 February 2017

Accepted for publication 17 March 2017

Published 18 April 2017 Volume 2017:10 Pages 2183—2188

DOI https://doi.org/10.2147/OTT.S134403

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Federico Perche

Peer reviewer comments 2

Editor who approved publication: Dr William Cho

Dawei Rong,1,* Weiwei Tang,1,* Zhouxiao Li,1,2,* Jian Zhou,3 Junfeng Shi,4 Hanjin Wang,1 Hongyong Cao1

1Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China; 2Department of Plastic and Hand Surgery, University Hospital Munich, Munich, Germany; 3Department of Oncology Surgery, 4Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China

*These authors contributed equally to this work

Abstract: Circular RNAs (circRNAs), formed by nonsequential back-splicing of pre-messenger RNA (pre-mRNA) transcripts, have been widely concerned in recent years. With advances in high-throughput RNA sequencing (RNA-seq) technology, previous work has revealed that a large number of circRNAs, which are endogenous, abundant and stable in mammalian cells, may be involved in atherosclerotic vascular disease risk, neurological disorders, prion diseases and carcinomas. Remarkably, interaction between circRNAs and microRNA has already been observed to perform a significant role in a variety of cancers, including gastric cancer and colorectal cancer. Recent work has suggested that circRNAs may play critical roles in the initiation and development of cancers and could become potential new biomarkers for cancers. Herein, we review the current understanding of the roles of circRNAs in cancers and the potential implications of circRNAs in cancer-targeted therapy.

Keywords: circular, targeted therapy, diagnosis, microRNA, noncoding RNA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

An isolated unusual digit metastasis from esophageal carcinoma: a case report

Chen Y, Tang W, Xiao H, Chen J, Zhao H, Shi J

OncoTargets and Therapy 2017, 10:2449-2452

Published Date: 9 May 2017

Health literacy and functional exercise adherence in postoperative breast cancer patients

Tang W, Li Z, Tang C, Wang X, Wang H

Patient Preference and Adherence 2017, 11:781-786

Published Date: 13 April 2017

Upregulation of MAGEA4 correlates with poor prognosis in patients with early stage of esophageal squamous cell carcinoma

Tang WW, Liu ZH, Yang TX, Wang HJ, Cao XF

OncoTargets and Therapy 2016, 9:4289-4293

Published Date: 14 July 2016

Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis

Tang WW, Huang CW, Tang CY, Xu J, Wang HJ

OncoTargets and Therapy 2016, 9:455-460

Published Date: 22 January 2016

Implication of lncRNAs in pathogenesis of esophageal cancer

Tang WW, Wu QQ, Li SQ, Tong YS, Liu ZH, Yang TX, Xu Y, Cao XF

OncoTargets and Therapy 2015, 8:3219-3226

Published Date: 3 November 2015